Medtronic Stock Is Climbing Friday: What's Going On?

On Wednesday, the Centers for Medicare & Medicaid Services (CMS) proposed a significant step toward broader adoption of renal denervation (RDN) by offering coverage for both radiofrequency (rfRDN) and ultrasound (uRDN) technologies for uncontrolled hypertension. This coverage would be granted under a Coverage with Evidence Development (CED) framework, requiring treatment within CMS-approved studies.

This proposal follows Medtronic Plc’s (NYSE:MDT) request for a national coverage determination for renal denervation in December 2024. RDN is a procedure that reduces activity in the renal nerves, located in the kidneys, to help lower blood pressure.

Medtronic’s Symplicity Spyral Renal Denervation System received U.S. Food and Drug Administration (FDA) premarket approval (PMA) in November 2023. With over 18 million people in the U.S. estimated to have uncontrolled hypertension (blood pressure >150 mmHg), Medtronic stands to capitalize on a potentially massive growth driver.

Also Read: